Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF – Get Free Report)’s stock price shot up 9.2% during mid-day trading on Wednesday . The company traded as high as $21.78 and last traded at $21.78. 2,800 shares were traded during trading, an increase of 71% from the average session volume of 1,633 shares. The stock had previously closed at $19.95.
Santhera Pharmaceuticals Price Performance
The business has a 50 day moving average price of $17.20 and a two-hundred day moving average price of $15.37.
About Santhera Pharmaceuticals
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative therapies for rare neuromuscular and pulmonary diseases. Headquartered in Pratteln, Switzerland, the company concentrates on addressing high unmet medical needs in conditions such as Duchenne muscular dystrophy (DMD), limb‐girdle muscular dystrophies and other mitochondrial or neuromuscular disorders. Santhera’s corporate strategy emphasizes both in‐house development and strategic partnerships to advance its drug candidates through clinical trials and bring approved therapies to market.
The company’s flagship marketed product is Raxone (idebenone), a synthetic analogue of coenzyme Q10 that received marketing authorization in Europe for the treatment of visual impairment in patients with Leber’s hereditary optic neuropathy (LHON).
Read More
- Five stocks we like better than Santhera Pharmaceuticals
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- 1,500 Banks Just Handed the Fed Your Bank Account
- Trump Planning to Use Public Law 63-43: Prepare Now
Receive News & Ratings for Santhera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santhera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
